2 results
Approved WMOCompleted
We here propose a pilot immuno-PET study in active relapsing MS patients to investigate safety and sensitivity of 89Zr-rituximab in detecting CD20 positive (active) MS lesions and to assess inter-patient variability in 89Zr-rituximab biodistribition…
Approved WMORecruiting
Objective 1: Compare the predictions of the EzaPredictive 1.0 ML models for hospital admission, ER LOS, and hospital LOS with healthcare professional predictions. Objective 2: Assess healthcare professional experience and acceptance of EzaPredictive…